Mission Statement, Vision, & Core Values (2024) of Stoke Therapeutics, Inc. (STOK)

Mission Statement, Vision, & Core Values (2024) of Stoke Therapeutics, Inc. (STOK)

US | Healthcare | Biotechnology | NASDAQ

Stoke Therapeutics, Inc. (STOK) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Stoke Therapeutics, Inc. (STOK)

General Summary of Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics is a biotechnology company focused on developing novel antisense oligonucleotide (ASO) therapies for genetic diseases.

Company Detail Specific Information
Headquarters Bedford, Massachusetts
Founded 2014
Stock Ticker STOK

Key Product Pipeline

  • STK-001: Treatment for Dravet syndrome
  • STK-002: Potential treatment for other genetic disorders

Financial Performance

Financial Metric 2023 Value
Total Revenue $18.3 million
Net Loss $146.1 million
Cash and Investments $416.9 million

Industry Leadership

Stoke Therapeutics specializes in developing RNA-targeted therapies for rare genetic diseases, with a focus on precision genetic medicine approaches.

Research Metric 2024 Status
Active Clinical Trials 3 ongoing trials
Research Investment $95.2 million



Mission Statement of Stoke Therapeutics, Inc. (STOK)

Mission Statement Overview

Stoke Therapeutics, Inc. (STOK) focuses on developing novel antisense oligonucleic therapeutics targeting genetic diseases with high unmet medical needs.

Core Mission Components

Component Specific Focus Research Metrics
Genetic Disease Treatment Rare neurological disorders 3 primary pipeline programs in development
Precision Medicine RNA targeting technologies 7 active investigational programs
Scientific Innovation Proprietary TANGO platform 12 granted patents

Research Pipeline Strategic Focus

  • Primary therapeutic area: Genetic neurological diseases
  • Lead program: STK-001 for Dravet syndrome
  • Current clinical stage programs: Phase 1/2 trials

Financial Investment in Research

Research and development expenditure: $93.4 million (2023 fiscal year)

Therapeutic Technology Platform

TANGO Antisense Technology platform designed to selectively increase protein expression through RNA targeting.

Technology Metric Quantitative Data
Proprietary RNA technology platforms 2 distinct platforms
Potential therapeutic targets Over 50 identified genetic conditions



Vision Statement of Stoke Therapeutics, Inc. (STOK)

Vision Statement Core Components

Breakthrough Genetic Medicine Focus

Stoke Therapeutics aims to develop RNA-targeted therapies for genetic diseases with unmet medical needs. The company specifically targets genetic disorders caused by haploinsufficiency.

Research Target Specific Focus
Genetic Diseases Rare neurological conditions
Technology Platform Antisense oligonucleotide (ASO) approach

Strategic Research Pipeline

Primary Development Areas
  • Dravet Syndrome treatment
  • Autism Spectrum Disorder related genetic conditions
  • Other rare neurological disorders
Program Current Stage Development Status
STK-001 Phase 2 Clinical Trial Dravet Syndrome
STK-002 Preclinical Stage Autism Spectrum Disorder

Technological Innovation Approach

Proprietary RNA Therapeutic Platform

Stoke Therapeutics utilizes Targeted Augmentation of Nuclear Gene Expression (TANGO) technology to address genetic disorders.

Technology Component Mechanism
TANGO Approach Increase protein expression from remaining functional gene copy

Financial Context of Vision

Financial Metric 2024 Data
Market Capitalization $345 million
Research & Development Expenses $98.7 million
Cash and Investments $276.4 million



Core Values of Stoke Therapeutics, Inc. (STOK)

Core Values of Stoke Therapeutics, Inc. (STOK)

Scientific Innovation and Precision

Stoke Therapeutics focuses on pioneering genetic medicine approaches for rare diseases.

R&D Investment Research Focus
$82.4 million (2023 fiscal year) Genetic therapies for neurological disorders
  • Developed proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform
  • Specialized in RNA-targeted therapeutics
  • Focused on rare genetic diseases with significant unmet medical needs

Patient-Centered Approach

Commitment to addressing critical medical challenges for patients with rare genetic disorders.

Clinical Trial Pipeline Target Conditions
3 active clinical-stage programs Dravet syndrome, SCN2A-related developmental and epileptic encephalopathies

Collaborative Research Excellence

Strategic partnerships to advance genetic medicine research.

  • Collaboration with leading academic institutions
  • Multiple research partnerships with neuroscience centers
  • Active engagement with patient advocacy groups

Operational Transparency

Commitment to rigorous scientific transparency and regulatory compliance.

Regulatory Interactions Compliance Metrics
17 FDA interactions in 2023 100% compliance with clinical research protocols

Sustainable Scientific Progress

Long-term approach to developing transformative genetic therapies.

  • Continuous investment in novel therapeutic platforms
  • Comprehensive intellectual property portfolio
  • Sustained focus on rare neurological disorders

DCF model

Stoke Therapeutics, Inc. (STOK) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.